3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Sarcoma
9
Rhabdomyosarcoma
5
Wilms Tumor
2
Ovarian Neoplasms
2
Melanoma
2
Malignant mesenchymal tumor
2
Gestational Trophoblastic Disease
2
Fibrosarcoma
2
Testicular Neoplasms
1
Teratoma, Ovarian
1
Sarcoma, Alveolar Soft Part
1
Rhabdoid Tumor
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Germ Cell and Embryonal
1
Liposarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangiopericytoma, Malignant
1
Desmoplastic Small Round Cell Tumor
1
Dermatofibrosarcoma
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cisplatin
8
Etoposide
6
Paclitaxel
5
Ifosfamide
4
Sunitinib
3
Oxaliplatin
3
Cyclophosphamide
3
Brentuximab Vedotin
3
tremelimumab
2
pembrolizumab
2
etoposide phosphate
2
durvalumab
2
Sirolimus
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Dexamethasone
2
Carboplatin
2
Bleomycin
2
Bevacizumab
2
tozuleristide
1
rolapitant
1
ribociclib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
fosaprepitant
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Germ Cell and Embryonal
×
Dactinomycin
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled